Abstract
Aspirin-exacerbated respiratory disease (AERD), the triad of asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and respiratory reactions to cyclooxygenase-1 inhibitors, is characterized by difficult-to-treat upper and lower respiratory symptoms. It is a type 2–mediated inflammatory disease marked by blood and tissue eosinophilia, dysregulated cysteinyl leukotriene production, and mast cell activation.1 Nasal polyposis in AERD is often severe and refractory to standard-of-care management including topical and systemic corticosteroids, endoscopic sinus surgery (ESS), and aspirin desensitization followed by high-dose daily aspirin.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of Allergy and Clinical Immunology: In Practice
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
